References
1. Roth G.A., Abate D., Abate K.H., et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1736–88.
2. Kornilova E.B., Ermolaeva A.D., Rusanova M.G., Andreev D.A., Davydovskaya M.V., Ermolaeva T.N., Pokatilo A.G., et al. The strategies of drug supply for patients with chronic hepatitis C. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya [Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology]. 2017; 10 (3): 34–46. DOI: https://doi.org/10.17749/2070-4909.2017.10.3.034-046 (in Russian)
3. Nahon P., Bourcier V., Layese R., Audureau E., Cagnot C., Marcellin P., et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017; 152: 142–56.
4. Bruno S., Di Marco V., Iavarone M., Roffi L., Crosignani A., Calvaruso V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016; 64: 1217–23.
5. Bakulin I.G., Oganezova I.A., Skalinskaya M.I., Skazyvaeva E.V. Liver cirrhosis and complication risk management. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (8): 963–8. DOI: https://doi.org/10.26442/00403660.2021.08.200917 (in Russian)
6. Rowe I.A. Lessons from epidemiology: the burden of liver disease. Dig Dis. 2017; 35 (4): 304–9. DOI: https://doi.org/10.1159/000456580
7. Mauro E., Crespo G., Montironi C., Londono M.C., Hernandez-Gea V., Ruiz P., et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018; 67 (5): 1683–94. DOI: https://doi.org/10.1002/hep.29557
8. Pol S., Haour G., Fontaine H., Dorival C., Petrov-Sanchez V., Bourliere M., et al.; French Anrs Co22 Hepather Cohort. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017; 46 (11–12): 1054–60. DOI: https://doi.org/10.1111/apt.14352
9. Stroffolini T., Sagnelli E., Andriulli A., Colloredo G., Furlan C., Gaeta G.B., et al. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. PLoS One. 2017; 12 (11): e0185710. DOI: https://doi.org/10.1371/journal.pone.0185710
10. Pimpin L., Cortez-Pinto H., Negro F., et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69 (3): 718–35. DOI: https://doi.org/10.1016/j.jhep/2018.05.011
11. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5: 245–66. Epub 2020 Jan 22. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8
12. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni [Infectious Diseases]. 2018; 16 (3): 37–45. DOI: https://doi.org/10.20953/1729-9225-2018-3-37-45 (in Russian)
13. Drapkina O.M., Samorodskaya I.V., Bolotova E.V., Starinskaya M.A. The nosological structure of years of potential life lost in the economically active age in the Russian Federation in 2016. Profilakticheskaya meditsina [Preventive Medicine]. 2019; 22 (1): 22–8. DOI: https://doi.org/10.17116/profmed20192201122 (in Russian)
14. Calvaruso V., Cabibbo G., Cacciola I., Petta S., Madonia S., Bellia A., et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018; 155: 411–21.
15. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020; 73 (5): 1170–218.
16. Hunyady B., Abonyi M., Gerlei Z., Gervain J., Horvath G., Jancsik V., et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin (3D + RBV) treatment of hepatitis C (HCV) genotype 1 (GT1) infected patients (pts) after failure to previous first generation protease-inhibitor (PI) therapy interim analysis. J Hepatol. 2016; 64 (2): 750.
17. Aghemo A., Cologni G., Maggiolo F., Pasulo L., Rizzardini G., Magni C., et al. Safety and efficacy of directly acting antivirals in 2432 HCV patients with advanced fibrosis: an interim analysis of the Lombardia regional network for viral hepatitis. J Hepatol. 2016; 64 (2): 213.
18. Forns X., Welzel T.M., Cohen E., Jacobson I.M., Davis M., Reindollar R.,
et al. Sustained virologic response predicts fibrosis regression measured by fibrotest in HCV-infected patients. J Hepatol. 2016; 64 (2): 829–30.